Kiniksa Pharmaceuticals International (KNSA) Change in Receivables (2021 - 2026)

Kiniksa Pharmaceuticals International has reported Change in Receivables for 6 years, with the latest figure at $7.6 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Receivables rose 559.92% year-over-year to $7.6 million; the trailing twelve-month figure through Mar 2026 stood at -$16.8 million (down 169.97% YoY), and the FY2025 full-year result was -$26.1 million, down 227.73% from the prior year.
• Change in Receivables for Q1 2026 stood at $7.6 million, up from -$36.1 million in the prior quarter.
• The five-year high for Change in Receivables was $25.5 million in Q1 2022, with the low at -$36.1 million in Q4 2025.
• Historically, Change in Receivables has averaged $1.1 million across 5 years, with a median of $3.4 million in 2022.
• The largest YoY upside for Change in Receivables was 1114.19% in 2023 against a maximum downside of 744.85% in 2023.
• Kiniksa Pharmaceuticals International's Change in Receivables stood at $1.5 million in 2022, then jumped by 1114.19% to $18.2 million in 2023, then declined by 7.62% to $16.8 million in 2024, then plunged by 314.71% to -$36.1 million in 2025, then surged by 121.11% to $7.6 million in 2026.
• The last three Change in Receivables figures came in at $7.6 million (Q1 2026), -$36.1 million (Q4 2025), and $19.8 million (Q3 2025), per Business Quant data.